Shares of Synta sank after news spread that its drug ganetespib spurred a 32% increase in survival for advanced lung cancer patients.
In the bid to propel personalized medicine into everyday use, Biodesix may have hit pay dirt. The company's recently concluded Phase III trial appears to show that its lung cancer blood diagnostic successfully predicts treatment outcomes for two different therapies.
Clovis Oncology managed to capture the spotlight at ASCO this morning with the news that the majority of advanced ovarian cancer patients in an early-stage trial benefited from their PARP inhibitor rucaparib. And in a clinical update Clovis also touted evidence of activity for its early-stage lung cancer drug targeted at EGFR-mutant patients. Its shares ($CLVS) skyrocketed 80% on the news.
U.S. researchers have developed a novel lung cancer treatment that uses nanoparticles to deliver an inhaled form of chemotherapy.
Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
A U.K. startup is partnering with a Japanese company in what has become an increasingly important focus for diagnostics developers: tests that can spot lung cancer in its earliest stages when there is a chance to beat it back.
CytRx has decided to dump a Phase IIb lung cancer study for the number-two drug program in the pipeline after the monitoring committee concluded that the trial was unlikely to find any improvement in progression-free survival compared to standard treatments.
Call it biomarker repurposing. Researchers have identified a compound produced by the body that can flag smokers at increased risk for lung cancer--a substance long used to gauge liver function.
An early snapshot of preliminary data from a midstage study of an experimental lung cancer drug at a Karolinska Development portfolio company offered an encouraging outline of its initial direction, persuading investigators to wrap enrollment earlier than initially planned as it completes the last leg of the trial.
The FDA has opened the inside track to Novartis' experimental lung cancer drug, which gained "Breakthrough Therapy" designation that speeds the development and review schedules for new treatments. The Swiss drug giant ($NVS) plans to file for approval the drug, now in mid-stage clinical trials, in early 2014.